Internal Medicine, Pulmonary Disease · Sacramento, CA
NPI
1992780209
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2221 Stockton Blvd
Sacramento, CA, 95817
Phone (916) 734-2011
Groups this clinician bills Medicare through
Medicare paid, 2024
$55K
1,125 services
Medicare patients, 2024
436
Average age 73
Drug cost, 2024
$4.5M
720 prescriptions
Company payments, 2025
$18K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brian M Morrissey was code 99232 (hospital e&m - subsequent), 133 times for 70 patients. In total Brian M Morrissey billed 1,125 services in 40 codes, and Medicare paid $55K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 133 | 70 | $63.14 | $8,398 |
| 99214 Office E&M - Established | Office | 93 | 70 | $73.00 | $6,789 |
| 94729 Pulmonary Function Testing | Office | 82 | 82 | $6.32 | $518 |
| 94729 Pulmonary Function Testing | Facility | 78 | 78 | $6.21 | $484 |
| 94726 Pulmonary Function Testing | Facility | 78 | 78 | $8.39 | $654 |
| 94726 Pulmonary Function Testing | Office | 76 | 76 | $8.59 | $653 |
| 99291 Critical Care E&M | Facility | 68 | 37 | $168.73 | $11K |
| 99233 Hospital E&M - Subsequent | Facility | 57 | 29 | $95.18 | $5,425 |
| 99222 Hospital E&M - Initial | Facility | 56 | 55 | $104.88 | $5,874 |
| 94010 Pulmonary Function Testing | Office | 49 | 49 | $5.94 | $291 |
| 94010 Pulmonary Function Testing | Facility | 46 | 46 | $6.06 | $279 |
| 99213 Office E&M - Established | Office | 43 | 34 | $48.16 | $2,071 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 39 | 38 | $13.07 | $510 |
| 94060 Pulmonary Function Testing | Office | 36 | 36 | $6.99 | $252 |
| 94060 Pulmonary Function Testing | Facility | 34 | 34 | $6.69 | $228 |
By year: 2022 $48K for 875 services; 2023 $64K for 1,037 services; 2024 $55K for 1,125 services.
Medicare prescription drug claims, 2024
In 2024, the drug Brian M Morrissey prescribed most often to Medicare patients was Ofev (Nintedanib Esylate), with 92 prescriptions and refills. In total Brian M Morrissey wrote 720 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ofev Nintedanib Esylate | 92 | 92 | 11 | $1.2M |
| Trikafta Elexacaftor/Tezacaftor/Ivacaft | 85 | 91 | 13 | $2.2M |
| Azithromycin Generic | 73 | 85 | 16 | $1,531 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 47 | 52 | 14 | $1,817 |
| Xolair Omalizumab | 28 | 28 | Under 11 | $113K |
| Symbicort Budesonide/Formoterol Fumarate | 25 | 25 | Under 11 | $5,512 |
| Esbriet Pirfenidone | 25 | 25 | Under 11 | $259K |
| Pirfenidone Generic | 21 | 21 | Under 11 | $101K |
| Cayston Aztreonam Lysine | 19 | 30 | Under 11 | $217K |
| Ethambutol Hcl Generic | 18 | 23 | Under 11 | $341 |
| Arikayce Amikacin Liposomal/Neb.Accessr | 18 | 18 | Under 11 | $263K |
| Mycophenolate Mofetil Generic | 18 | 26 | Under 11 | $7,528 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 17 | 17 | Under 11 | $72.06 |
| Advair Hfa Fluticasone Propion/Salmeterol | 17 | 17 | Under 11 | $4,838 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 14 | 14 | Under 11 | $746 |
Brand drugs: 480 claims; generic drugs: 224 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brian M Morrissey $18K ($18K in general payments such as food, travel and fees) from 5 companies. The largest payer was Insmed, Inc. with $18K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.